Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Edap Tms (EDAP) Stock Price

News headlines about Edap Tms (NASDAQ:EDAP) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Edap Tms earned a news sentiment score of 0.19 on Accern’s scale. Accern also gave press coverage about the medical equipment provider an impact score of 46.18936643813 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the media headlines that may have impacted Accern’s rankings:

Shares of Edap Tms remained flat at $$3.14 during midday trading on Friday, reports. The stock had a trading volume of 19,752 shares, compared to its average volume of 63,877. The company has a market capitalization of $91.05 million, a P/E ratio of -314.00 and a beta of 0.62. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.04 and a current ratio of 2.45. Edap Tms has a 1 year low of $2.07 and a 1 year high of $4.25.

Edap Tms (NASDAQ:EDAP) last announced its quarterly earnings results on Monday, May 14th. The medical equipment provider reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.05. The firm had revenue of $11.28 million for the quarter, compared to the consensus estimate of $10.46 million. Edap Tms had a negative return on equity of 5.89% and a negative net margin of 5.98%. sell-side analysts expect that Edap Tms will post -0.01 EPS for the current year.

EDAP has been the topic of several analyst reports. HC Wainwright reissued a “buy” rating and issued a $6.50 target price on shares of Edap Tms in a report on Monday, July 2nd. ValuEngine raised Edap Tms from a “hold” rating to a “buy” rating in a report on Monday, July 16th. Finally, TheStreet downgraded Edap Tms from a “c” rating to a “d+” rating in a report on Tuesday, May 15th.

About Edap Tms

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).

Further Reading: How to Use the New Google Finance Tool

Insider Buying and Selling by Quarter for Edap Tms (NASDAQ:EDAP)

Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit